May 13, 2021
Sumitomo Dainippon Pharma saw its group revenue rise 6.9% in the year through March 2021 on the back of the strong performance of its antipsychotic Latuda (lurasidone) in North America and its diabetes franchise in Japan. According to its earnings...read more